Member Posts > Cardiol Therapeutics' (NASDAQ: CRDL) (TSX: CRDL) CardiolRx: Transforming Pericarditis Treatment:
Recurrent pericarditis is a distressing inflammatory heart condition that can severely impact patients' quality of life. Current treatments, including NSAIDs, colchicine, and corticosteroids, often fall short, leading to repeated flare-ups and long-term side effects.
CardiolRx is advancing research with its pharmaceutical-grade cannabidiol (CBD) formulation, which is being evaluated for its anti-inflammatory and cardioprotective properties. Through an ongoing Phase II clinical trial, this therapy aims to reduce symptoms and recurrence, offering a promising new option for patients in need.

#CardiolTherapeutics #HeartHealth #MedicalInnovation #CardiacCare #PatientStories #Myocarditis #Pericarditis #HealthcareResearch #CommunityEngagement #CannabidiolResearch #HeartDiseaseAwareness #AdvancedTherapies #CardiolRx #CRD38